AACR 2021: Addition of Copanlisib to Rituximab Improves Outcomes in Indolent Non-Hodgkin Lymphoma
Benefits were observed across all disease subtypes
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Benefits were observed across all disease subtypes
Only registered members have full access to PracticeUpdate content.